HBIO
Price
$6.12
Change
-$0.02 (-0.33%)
Updated
Jul 13 closing price
Capitalization
27.51M
17 days until earnings call
Intraday BUY SELL Signals
NEOG
Price
$9.65
Change
+$0.03 (+0.31%)
Updated
Jul 13 closing price
Capitalization
2.1B
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

HBIO vs NEOG

HBIO vs NEOG Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
HBIO vs. NEOG commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HBIO is a Buy and NEOG is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (HBIO: $6.14 vs. NEOG: $9.65)
Brand notoriety: HBIO and NEOG are both not notable
HBIO represents the Pharmaceuticals: Other, while NEOG is part of the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: HBIO: 17% vs. NEOG: 37%
Market capitalization -- HBIO: $27.51M vs. NEOG: $2.1B
HBIO [@Pharmaceuticals: Other] is valued at $27.51M. NEOG’s [@Medical/Nursing Services] market capitalization is $2.1B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $144.19B to $0. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $160.44B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $7.95B. The average market capitalization across the [@Medical/Nursing Services] industry is $5.65B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HBIO’s FA Score shows that 1 FA rating(s) are green whileNEOG’s FA Score has 1 green FA rating(s).

  • HBIO’s FA Score: 1 green, 4 red.
  • NEOG’s FA Score: 1 green, 4 red.
According to our system of comparison, both HBIO and NEOG are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HBIO’s TA Score shows that 6 TA indicator(s) are bullish while NEOG’s TA Score has 6 bullish TA indicator(s).

  • HBIO’s TA Score: 6 bullish, 3 bearish.
  • NEOG’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, NEOG is a better buy in the short-term than HBIO.

Price Growth

HBIO (@Pharmaceuticals: Other) experienced а -0.16% price change this week, while NEOG (@Medical/Nursing Services) price change was +1.47% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.44%. For the same industry, the average monthly price growth was +7.29%, and the average quarterly price growth was -8.61%.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +7.62%. For the same industry, the average monthly price growth was -1.16%, and the average quarterly price growth was -16.57%.

Reported Earning Dates

HBIO is expected to report earnings on Jul 30, 2026.

NEOG is expected to report earnings on Jul 28, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (-2.44% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Medical/Nursing Services (+7.62% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NEOG($2.1B) has a higher market cap than HBIO($27.5M). NEOG YTD gains are higher at: 38.054 vs. HBIO (-8.493). HBIO has higher annual earnings (EBITDA): 1.45M vs. NEOG (-441.42M). NEOG has more cash in the bank: 160M vs. HBIO (7.1M). HBIO has less debt than NEOG: HBIO (44.1M) vs NEOG (793M). NEOG has higher revenues than HBIO: NEOG (871M) vs HBIO (85.5M).
HBIONEOGHBIO / NEOG
Capitalization27.5M2.1B1%
EBITDA1.45M-441.42M-0%
Gain YTD-8.49338.054-22%
P/E RatioN/A865.00-
Revenue85.5M871M10%
Total Cash7.1M160M4%
Total Debt44.1M793M6%
FUNDAMENTALS RATINGS
HBIO vs NEOG: Fundamental Ratings
HBIO
NEOG
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
97
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
4345
P/E GROWTH RATING
1..100
22
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NEOG's Valuation (97) in the Medical Specialties industry is in the same range as HBIO (100) in the Biotechnology industry. This means that NEOG’s stock grew similarly to HBIO’s over the last 12 months.

NEOG's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as HBIO (100) in the Biotechnology industry. This means that NEOG’s stock grew similarly to HBIO’s over the last 12 months.

NEOG's SMR Rating (98) in the Medical Specialties industry is in the same range as HBIO (99) in the Biotechnology industry. This means that NEOG’s stock grew similarly to HBIO’s over the last 12 months.

HBIO's Price Growth Rating (43) in the Biotechnology industry is in the same range as NEOG (45) in the Medical Specialties industry. This means that HBIO’s stock grew similarly to NEOG’s over the last 12 months.

HBIO's P/E Growth Rating (2) in the Biotechnology industry is in the same range as NEOG (2) in the Medical Specialties industry. This means that HBIO’s stock grew similarly to NEOG’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HBIONEOG
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
74%
Momentum
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
62%
MACD
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
71%
Bullish Trend 4 days ago
68%
Advances
ODDS (%)
Bullish Trend 21 days ago
71%
Bullish Trend 12 days ago
71%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 21 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 4 days ago
71%
Bullish Trend 4 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
HBIO
Daily Signal:
Gain/Loss:
NEOG
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MUD11.33N/A
N/A
Direxion Daily MU Bear 1X Shares
PMAP27.25N/A
N/A
PGIM S&P 500 Max Buffer ETF - April
BIZD12.47-0.08
-0.64%
VanEck BDC Income ETF
FCPI54.22-0.39
-0.72%
Fidelity Stocks for Inflation ETF
SPXV82.24-0.72
-0.87%
ProShares S&P 500® ex-Health Care

HBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with IRMD. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then IRMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HBIO
1D Price
Change %
HBIO100%
-0.33%
IRMD - HBIO
46%
Loosely correlated
+0.50%
A - HBIO
37%
Loosely correlated
-0.19%
RVTY - HBIO
36%
Loosely correlated
-1.05%
MTD - HBIO
35%
Loosely correlated
+0.26%
NEOG - HBIO
34%
Loosely correlated
+0.31%
More